Roffman Miller Associates Inc. PA Purchases 1,551 Shares of Thermo Fisher Scientific Inc. $TMO

Roffman Miller Associates Inc. PA grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.1% during the 2nd quarter, Holdings Channel reports. The firm owned 38,953 shares of the medical research company’s stock after purchasing an additional 1,551 shares during the period. Roffman Miller Associates Inc. PA’s holdings in Thermo Fisher Scientific were worth $15,794,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of TMO. Connable Office Inc. boosted its stake in Thermo Fisher Scientific by 1.7% in the second quarter. Connable Office Inc. now owns 5,639 shares of the medical research company’s stock valued at $2,286,000 after acquiring an additional 94 shares during the last quarter. Bridgewater Advisors Inc. boosted its position in shares of Thermo Fisher Scientific by 6.3% in the 2nd quarter. Bridgewater Advisors Inc. now owns 2,350 shares of the medical research company’s stock worth $953,000 after purchasing an additional 140 shares during the last quarter. Freestone Capital Holdings LLC increased its holdings in Thermo Fisher Scientific by 6.5% in the second quarter. Freestone Capital Holdings LLC now owns 29,135 shares of the medical research company’s stock valued at $11,813,000 after purchasing an additional 1,771 shares during the last quarter. Westside Investment Management Inc. lifted its stake in Thermo Fisher Scientific by 169.4% in the second quarter. Westside Investment Management Inc. now owns 97 shares of the medical research company’s stock valued at $41,000 after buying an additional 61 shares during the period. Finally, South Dakota Investment Council boosted its holdings in Thermo Fisher Scientific by 411.5% during the second quarter. South Dakota Investment Council now owns 40,952 shares of the medical research company’s stock worth $16,604,000 after buying an additional 32,946 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This represents a 13.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 54,420 shares of company stock valued at $28,134,684 in the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on TMO. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Leerink Partners boosted their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Finally, Citigroup boosted their target price on Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $565.19 on Tuesday. The company has a fifty day moving average price of $512.35 and a 200 day moving average price of $458.87. The firm has a market cap of $213.42 billion, a PE ratio of 32.65, a PEG ratio of 3.27 and a beta of 0.77. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.